Xenetic Biosciences Q2 2025 net loss $0.7M; cash $4.8M; expands Scripps partnership

Xenetic Biosciences, Inc.

2025-Q2 EPS reported -$1.03 vs consensus -$0.65 ▼ miss (-57.8%)

Net loss ~$0.7M for Q2 2025; no revenue reported.
R&D expenses fell 29.7% to ~$0.7M; G&A down 41.8% to ~$0.7M vs Q2 2024.
Cash at quarter-end ~$4.8M to fund operations.
Expanded collaboration with Scripps Research Institute for DNase I plus CAR T-cell studies.
Partner PeriNess commenced patient dosing in pancreatic cancer study; exploratory CAR T study in large B cell lymphoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.